Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 4.4 | 5.7 | 6.2 | 7.1 | 8.4 | 10.1 | 11.6 | 11.9 |
| Operating profit | $bn | 2.95 | 3.28 | ||||||
| Net profit | $bn | 1.06 | 1.70 | 1.32 | 1.80 | 2.32 | 2.86 | 2.96 | 4.08 |
| EPS reported | $ | 7.87 | 8.33 | ||||||
| Operating cashflow per share | $ | 8.49 | 11.72 | ||||||
| Capex per share | $ | 1.51 | 1.41 | ||||||
| FCF per share | $ | 6.98 | 10.31 | ||||||
| Free cash flow | $bn | 2.49 | 3.60 | ||||||
| Net debt | $bn | -5.76 | -4.04 | ||||||
| Book value equity | $bn | 17.8 | 16.0 | ||||||
| Book value per share | $ | 49.14 | 45.47 | ||||||
| Number of shares | m | 362.7 | 351.6 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 71.96 | 54.03 | ||||||
| P/B LTM | x | 11.34 | 9.76 | ||||||
| P/S LTM | x | 20.08 | 13.47 | ||||||
| P/FCF LTM | x | 81.16 | 43.36 | ||||||
| EV/EBITDA LTM | x | 49.91 | 36.26 | ||||||
| EV/Sales LTM | x | 19.78 | 13.12 | ||||||
| Earnings Yield LTM | % | 1.39% | 1.85% | ||||||
| FCF Yield | % | 1.23% | 2.31% | ||||||
| Quality | |||||||||
| ROE | % | 16.02% | 17.03% | ||||||
| ROIC | % | 13.71% | 16.04% | ||||||
| Operating margin | % | 29.27% | 28.37% | ||||||
| Gross margin | % | 66.00% | 67.19% | ||||||
| FCF/Sales | % | 24.75% | 31.08% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +22.59% | +10.19% | ||||||
| Sales Growth YoY | % | +20.51% | +20.45% | ||||||
| Net Income Growth YoY | % | +22.97% | +7.66% | ||||||
| FCF Growth | % | +91.03% | +58.41% | ||||||
| Operating Profit Growth | % | +25.40% | +16.62% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 8.23 | - | ||||||
| Net Debt/EBITDA | x | -0.77 | -0.71 | ||||||
| EBIT/Net interest | x | - | - | ||||||
| Net debt/market cap | % | -2.85% | -2.59% | ||||||
| Net debt/Equity | x | -0.32 | -0.25 | ||||||
| Gross debt/equity | x | 0.02 | 0.00 | ||||||
ETFs that hold Intuitive Surgical
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Invesco S&P 500 Equal Weight ETF | RSP | 5 | 0.26% |
| Xtrackers S&P 500 Equal Weight UCITS ETF 2C EUR Hedged | XDEE.DE | 5 | 0.26% |
| Xtrackers II | XDEW.L | 5 | 0.26% |
| iShares S&P 500 Equal Weight UCITS ETF USD (Acc) | EWSP.L | 5 | 0.26% |
| iShares Automation & Robotics UCITS ETF | RBOT.L | 5 | 3.38% |
| iShares U.S. Medical Devices ETF | IHI | 2 | 14.85% |
| Global X - Robotics & Artificial Intelligence ETF | BOTZ | 1 | 10.91% |
| Invesco S&P 100 Equal Weight ETF | EQWL | 2 | 1.35% |
| Invesco S&P 500 Equal Weight UCITS ETF (Acc) | SPEQ.L | 5 | 0.26% |
| ROBO Global Robotics and Automation Index ETF | ROBO | 1 | 2.52% |
Funds with Intuitive Surgical among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Intuitive Surgical, Inc. (ISRG)
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Invesco S&P 500 Equal Weight ETF | RSP | 5 | 0.26% |
| Xtrackers S&P 500 Equal Weight UCITS ETF 2C EUR Hedged | XDEE.DE | 5 | 0.26% |
| Xtrackers II | XDEW.L | 5 | 0.26% |
| iShares S&P 500 Equal Weight UCITS ETF USD (Acc) | EWSP.L | 5 | 0.26% |
| iShares Automation & Robotics UCITS ETF | RBOT.L | 5 | 3.38% |
| iShares U.S. Medical Devices ETF | IHI | 2 | 14.85% |
| Global X - Robotics & Artificial Intelligence ETF | BOTZ | 1 | 10.91% |
| Invesco S&P 100 Equal Weight ETF | EQWL | 2 | 1.35% |
| Invesco S&P 500 Equal Weight UCITS ETF (Acc) | SPEQ.L | 5 | 0.26% |
| ROBO Global Robotics and Automation Index ETF | ROBO | 1 | 2.52% |
Funds with Intuitive Surgical among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free